ortataxel (BAY 59-8862) / Spectrum Pharma, Assertio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ortataxel (BAY 59-8862) / Assertio
NCT00044564: Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Completed
2
54
US, Canada, Europe
Bay 59-8862
Bayer
Carcinoma, Renal Cell
 
01/03
NCT00054314: BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer

Completed
2
NA
ortataxel
Roswell Park Cancer Institute
Lung Cancer
04/03
 
NCT00044551: Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Completed
2
29
US, Canada, Europe
Taxane (Cytotoxic, BAY59-8862)
Bayer
Lymphoma, Non-Hodgkin
 
07/03
NCT00044525: Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

Completed
2
82
Europe, RoW
BAY59-8862 (Cytotoxic Taxane)
Bayer
Breast Neoplasms, Breast Cancer, Metastatic
02/04
02/04
NCT00044538: Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

Completed
2
102
US, Canada, Europe, RoW
BAY59-8862 (Cytotoxic Taxane)
Bayer
Carcinoma, Non-Small-Cell Lung
 
06/04
NCT00039169: BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

Unknown status
2
Canada, US
ortataxel
Theradex
Kidney Cancer
 
 
NCT00039156: BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Unknown status
2
Canada, US
ortataxel
Theradex
Lymphoma
 
 
IRFMN-GBM-6272, NCT01989884 / 2012-003618-15: An Efficacy Study Of Ortataxel In Recurrent Glioblastoma

Completed
2
45
Europe
Ortataxel, IDN5109
Mario Negri Institute for Pharmacological Research
Glioblastoma
12/15
12/16

Download Options